CEREBROLYSIN 5 AMP 5 ML سيريبروليسين 5 أمب 5 مل

Cerebrolysin 5ml – 5 ampoules of 5 ml. Solution for injection / concentrate for solution for infusion.
* Administration: Intramuscular (I.M.) or I.V. (intravenous) use.
* Active ingredient: 1ml contains: 215.2mg of Cerebrolysin concentrate in aqueous solution. Excipients: Sodium hydroxide, water for injection.
* For the modern, safe and effective treatment of disturbed cerebral functions.
* Indications:
– Disturbances of concentration && memory.
– Degenerative dementias, including Alzheimer’s disease.
– Vascular dementias, e.g. multi-infarct dementia.
– Mixed forms of dementia (degenerative && vascular contribution).
– Sequels of stroke (ischaemic && haemorrhagic).
– Posttraumatic or postoperative complaints e.g., following cerebral contusion, concussion, or neurosurgical operation.
* Contra-indications:
– Status epilepticus or grand mal convulsions; an increase in the seizure frequency may be seen in these cases.
– Severe impairment of renal function.
* Warnings and precautionary measures:
& Patients with severe renal impairment must be excluded from a Cerebrolysin therapy. Animal experimental data did
& not show any evidence of teratogenic effects. There is no clinical experience with Cerebrolysin in pregnant women.
& Therefore, unless the potential benefits outweigh any potential risk, Cerebrolysin should not be administered during
& pregnancy and the lactation period.
* Interactions: Concomitant administration of Cerebrolysin with antidepressive drugs or MAO inhibitors can lead to cumulative effects.
& In these cases a dose reduction of the antidepressive drug is advisable.
* Dosage: Cerebrolysin is available in 1mL, 5mL and 10mL ampoules and in vials of 30mL and 50mL. Up to 5mL per
& intramuscular administration, for administrations over 5mL an intravenous injection or infusion is advised.
& Cerebrolysin can also be given diluted in a standard IV solution (eg. physiological saline solution, Ringer’s
& solution, glucose 5%, dextran 40) infused slowly over approximately 20 to 60 minutes. Once daily applications
& of Cerebrolysin for a minimum of 10 to 20 days are recommended. This constitutes a course of therapy.
& In mild cases 1-5mL, in severe cases 10-30mL should be applied. The length of the therapy and the individual
& doses depends on the age of the patient as well as on the severity of the disease. Usually a treatment period
& of 3 to 4 weeks is recommended. Therapy courses can be repeated several times in accordance with the
& clinical picture of the patient until no further improvement can be observed. Therapy-free intervals should be
& maintained between courses. In severe cases it is advisable not to interrupt treatment abruptly but to continue
& with one injection every other day for a period of 4 weeks.